Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Monday

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.09. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rapport Therapeutics Stock Performance

RAPP traded down $1.33 on Thursday, hitting $8.18. 115,096 shares of the company were exchanged, compared to its average volume of 174,168. The firm has a fifty day simple moving average of $10.12 and a two-hundred day simple moving average of $14.17. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74. The stock has a market capitalization of $298.41 million and a PE ratio of -2.37.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RAPP shares. JMP Securities started coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They set a "market outperform" rating and a $28.00 price target on the stock. Citizens Jmp started coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. Four analysts have rated the stock with a buy rating, According to data from MarketBeat, Rapport Therapeutics has an average rating of "Buy" and a consensus price target of $32.67.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, Director Wendy B. Young acquired 6,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the transaction, the director now owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Troy A. Ignelzi bought 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The stock was purchased at an average price of $10.10 per share, with a total value of $99,990.00. Following the purchase, the chief financial officer now owns 9,900 shares in the company, valued at $99,990. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock valued at $144,000 after purchasing an additional 4,109 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new position in shares of Rapport Therapeutics in the 1st quarter valued at approximately $2,039,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after purchasing an additional 4,582 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.